Cargando…
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK sam...
Autores principales: | Luo, Man (Melody), Usmani, Saad Z., Mateos, Maria‐Victoria, Nahi, Hareth, Chari, Ajai, San‐Miguel, Jesus, Touzeau, Cyrille, Suzuki, Kenshi, Kaiser, Martin, Carson, Robin, Heuck, Christoph, Qi, Ming, Zhou, Honghui, Sun, Yu‐Nien, Parasrampuria, Dolly A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048619/ https://www.ncbi.nlm.nih.gov/pubmed/33145788 http://dx.doi.org/10.1002/jcph.1771 |
Ejemplares similares
-
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
por: Iida, Shinsuke, et al.
Publicado: (2021) -
Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018) -
Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
por: Ruiz‐Garcia, Ana, et al.
Publicado: (2020) -
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020) -
Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)